The oral solution, Sabril [vigabatrin], has been approved by the FDA for children between the ages of one month and two years and is the first drug to treat infantile spasms which is a rare disorder leading to hundreds of seizures in children under a year old. During testing scientists believed that the disorder was caused by a deficit of gamma-amino-butyric acid (GABA) in the brain so developed the drug as a "suicide inhibitor of the enzyme gamma-aminobutyric acid transaminase" which breaks down GABA. The drug will carry a black box warning about the risk of a progressive loss of peripheral vision with potential decrease in visual acuity and will be available through a restricted distribution program.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지